Hemodialysis for acute kidney injury

Series
Nephrology and Urology
Status
Published
Date
Number of report
079

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of hemodialysis as treatment for acute kidney injury. The analysis will cover adult patients only.

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of equipment of hemodialysis for acute kidney injury:

  • Allmed Group (POLYPURE, HF)
  • Asahi Kasei Medical (MDS-101, APS, Rexeed, ViE, KF-201, Cureflo)
  • B. Braun (OMNI, Diapact CRRT, OMNIfilter, Haemoselect, Diacap, Dialog iQ, Xevonta, Diacap Pro)
  • Baxter (Theranova, Prismaflex, Prismax, Phoenix X36, Polyflux 6H, Revaclear, Artis Physio)
  • Bellco/Medtronic (SIMPLY BEYOND, AMPLYA, CARPEDIEM)
  • Biolight Meditech (D-30, DTB-100F, DTB-100)
  • CR Bard/ BD (Decathlon, Equistream, Glidepath, Hemosplit, Hickman, Reliance, Soft-cell, Power-trialysis, DuoGlide, Brevia, Niagara)
  • Dialife Group (Diadvance)
  • Informed (HF440)
  • Farmasol (Dialyzer, Catridge)
  • Kawasumi Laboratories (Dialyzers)
  • Fresenius (multiFiltratePRO, multiFiltrate)
  • Landwind Medical (AISO-3038, JHM-2028A, JHM-2028M, JH-4048, JH-5058)
  • Medivators/Cantel
  • Nikkiso (Aquarius, DBB-EXA, DBB-07, DBB-06, DBB-27, FDX, FDY)
  • Nipro Medical (Surdial-X, Surdial – 55Plus, Elisio, Sureflux, Solacea)
  • Medica (ACUSmart, Smartflux)
  • Serumwerk Bernburg (Dialyzers, cartridges)
  • SWS Medical (SWS-6000, SWS-4000, SWS-5000)
  • Toray Medical (TQS-88, TR-8000)
  • Outset Medical (Tablo)

Table of content is not available at the moment. Report is still ongoing.

29

Sep 2021

In August 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (magnetic resonance therapy for knee osteoarthritis, laparoscopic removal of uterine fibroids with power morcellation, hysteroscopic mechanical tissue removal for uterine fibroids), and six new Medtech Innovation Briefings (PLASMA system with button electrode, Immunoscore, MMprofiler, Patient Status Engine, lung texture analysis, Colli-Pee). Also, five clinical guidelines were published.

Read more

27

Sep 2021

In August 2021, 22 Russian clinical guidelines in the fields of ENT, cardiovascular, obstetrics and gynecology, orthopedics and others, were released. Furthermore, the order on the approval of the standard of medical care for adults with urolithiasis disease entered into force.

Read more

23

Sep 2021

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 14763 of August 25, 2021, Tuscany Regional Healthcare has published assessments of thirteen medical devices of various therapeutic areas, including devices belonging to the obstetrics and gynecology field, as well as gastroenterology, urology, cardiovascular, endoscopy, spine, peripheral vascular, and other fields of care.

Read more

24

Aug 2021

In July 2021, 31 clinical guidelines were released in Russia: irritable bowel syndrome, rectal prolapse, chronic kidney disease, and others. Furthermore, the orders on the approval of the several standards of medical care entered into force, including standards for the provision of medical care for adults with acute ST-elevation myocardial infarction, hemorrhoids, and anal fistula.

Read more

09

Jun 2021

For the first time in three years, the Institute for Quality and Efficiency in Health Care (IQWiG) received data within the framework of the early benefit assessment of new examination and treatment methods (NUB) with high-risk medical devices according to §137h of Social Code Book (SGB) V. This involves seven invasive therapeutic cardiovascular, pulmonary, neurological, gastrointestinal, and urological procedures.

Read more
(we accept only company emails)